Biosimilars: A 2020 Mid-Year Review

Biologics are the fastest-growing class of therapeutic products in the United States. In 2019, the FDA approved 10 biosimilars a new record. For pharmaceutical companies, this means that competition in the biosimilars space is heating up and creating a new sense of urgency to innovate.

In this webinar, life sciences attorneys John Adkisson, Geoff Biegler, and Jenny Shmuel provided a mid-year update on the current U.S. biosimilars space. Topics that were discussed include recent developments regarding:

• The U.S. biosimilars market, including approvals and launches
• FDA announcements and guidance
• Select court cases and appellate guidance
• Trends in IPRs

In addition, our hosts discussed how the ongoing COVID-19 pandemic has impacted U.S. biosimilars and how it could continue to do so in the future.

Presenters: John Adkisson, Geoff Biegler, Jenny Shmuel

To access a recording of this webinar or receive a copy of the slides, please contact [email protected].